{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319626172288.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1185/030079904x20240"}},{"identifier":{"@type":"URI","@value":"http://www.tandfonline.com/doi/pdf/10.1185/030079904X20240"}}],"dc:title":[{"@value":"Ocular penetration of moxifloxacin 0.5% and gatifloxacin 0.3% ophthalmic solutions into the aqueous humor following topical administration prior to routine cataract surgery"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670319626172290","@type":"Researcher","foaf:name":[{"@value":"Dianne H. Kim"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319626172289","@type":"Researcher","foaf:name":[{"@value":"Walter J. Stark"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319626172288","@type":"Researcher","foaf:name":[{"@value":"Terrence P. O'Brien"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03007995"},{"@type":"EISSN","@value":"14734877"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/03007995"}],"prism:publicationName":[{"@value":"Current Medical Research and Opinion"}],"dc:publisher":[{"@value":"Informa Healthcare"}],"prism:publicationDate":"2005-01-05","prism:volume":"21","prism:number":"1","prism:startingPage":"93","prism:endingPage":"94"},"reviewed":"false","url":[{"@id":"http://www.tandfonline.com/doi/pdf/10.1185/030079904X20240"}],"createdAt":"2005-02-10","modifiedAt":"2016-12-13","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1390001204272431232","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pharmacodynamic profile and clinical efficacy of moxifloxacin ophthalmic solution (VegamoxTM 0.5% ophthalmic solution)"},{"@language":"ja","@value":"モキシフロキサシン点眼液（ベガモックス点眼液０．５％）の薬理学的特性および臨床効果"},{"@value":"新薬紹介総説 モキシフロキサシン点眼液(ベガモックス点眼液0.5%)の薬理学的特性および臨床効果"},{"@language":"ja-Kana","@value":"シンヤク ショウカイ ソウセツ モキシフロキサシン テンガンエキ ベガモックス テンガンエキ 0 5% ノ ヤクリガクテキ トクセイ オヨビ リンショウ コウカ"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1185/030079904x20240"},{"@type":"CROSSREF","@value":"10.1254/fpj.129.375_references_DOI_TXLsGqGCgkjP3B8vCnxuiDhVgHN"}]}